About
Aims and scope
The Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed, online journal of the Society for Immunotherapy of Cancer (SITC). The journal publishes articles on all aspects of tumor immunology and cancer immunotherapy and, in doing so, aims to enrich communication and advance scientific understanding among the many stakeholders in this rapidly evolving field. Topics of interest range widely across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.
Editorial Board
For information about JITC Editor-in-Chief Pedro Romero and his editorial team, please refer to the Editorial Board page.
Ownership
BMJ publishes JITC on behalf of the Society for Immunotherapy of Cancer.
Journal information
| Publication Model | Open access |
|---|---|
| Frequency | Continuous |
| Launch date | 2013 |
| Digital Archive | LOCKSS |
| Indexed by | Web of Science Core Collection: Science Citation Index Expanded; MEDLINE, PubMed Central, Science Citation Index Expanded (SCIE), Scopus, DOAJ, Google Scholar |
| Impact Factor | 8.728 (2018) |
| CiteScore | 6.86 (2018) |
| Peer Review Model | Single blind; the names of reviewers are hidden from the author |
| Print ISSN | N/A |
| Online ISSN | 2051-1426 |
Journal statistics (2018)
| Acceptance Rate | |
|---|---|
| Mean time from submission to first decision | 44 days |
| Time from acceptance to online publication | 21 days |
Contact information
For all contact information please refer to the contact us page.
For Authors
Please refer to the Instructions for authors.
Subscriptions
To advertise
Rights and permissions
Affiliations
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Its mission is to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.
BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.
The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.
BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.